Kreaxi
  • Home
  • Company
  • Funds
  • Team
  • Portfolio
  • News
  • Contact
  • Français
Select Page

Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.

Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells (the “Company”), presents an update on its activities and...

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to AZP-3601, the company’s clinical...

Recent Posts

  • Theranexus : 2020 full-year results and update on the progress of main programs
  • Flexitron Group, the Spanish group dedicated to IoT markets acquires majority stake in Webdyn SA to extend its footprint in the energy transition market.
  • Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)
  • Linkfluence is joining forces with Meltwater to accelerate is leadership in aI-enabled consumer insights
  • Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.

Recent Comments

    Archives

    • April 2021
    • March 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • July 2020
    • April 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • July 2019
    • March 2019
    • February 2019
    • December 2018
    • November 2018
    • December 2017
    • September 2017
    • April 2017

    Categories

    • News portfolio

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About us

    Kreaxi is an investment management firm specialized in the equity financing of innovative, deeptech & lowtech startups with high growth potential. Kreaxi manages regional funds in France, focusing on Auvergne-Rhône-Alpes region as well as French and pan-european funds.

    Lyon

    101, Chemin Vert
    69760 Limonest 
    France

    +33 4 72 52 39 39

    Paris

    13-15 rue Taitbout
    75009 Paris
    France

    +33 1 73 02 89 69

    Register to recieve our Krea-Venture newsletter

    • Twitter
    © 2021 Kreaxi. Tous droits réservés. Mentions légales. Informations réglementaires. Démarche ESG.